Micro Market Research
US/CAN Toll Free

You are here :   Home     Healthcare     Pharmaceuticals     Drug formulations     Chronic lymphocytic leukemia (CLL)    
Real Time Market Research & Industry Analysis - MicroMarketMonitor

Global Campath/MabCampath Market Research Report

  • Report Code: CA 1000
  • Publish Date: Upcoming
Table of Contents
Customer Intelligence
Inquiry Before Buying Ask for Discount
Campath/MabCampath and Treanda, Arzerra, Fludara, FCR Regimen and FC Regimen adds up to total Marketed Drugs (CLL) market.

Campath/MabCampath can be segmented by Geographies and Companies. Geographies of this market are USA, Canada, United Kingdom, Germany, France, Italy, Spain and Japan. Companies of this market are Genzyme Corporation, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals, Inc (cephalon).


Key Questions Answered

  • What are market estimates and forecasts; which of Campath/MabCampath markets are doing well and which are not?
  • What is the competitive landscape; How companies like Genzyme Corporation, Glaxosmithkline Plc and F. Hoffmann-La Roche Ltd. doing in Campath/MabCampath?

    What makes our report unique?

    • This report provides market sizing and forecast for the Campath/MabCampath market. It also provides market sizing and forecast along with the drivers/inhibitors/opportunity analysis for each of the micro markets.
    • The report provides deep dive competitive landscape covering the top players such as Genzyme Corporation, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals, Inc (cephalon).
    • The reports provides benchmarking insight on the top players Genzyme Corporation, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals, Inc (cephalon).
    • The report provide competitive intelligence on Genzyme Corporation, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals, Inc (cephalon).

      Audience for this report

      • Global Campath/MabCampath companies
      • Manufacturing Companies
      • Traders, distributors, and suppliers
      • Governmental and research organizations
      • Associations and industry bodies
      • Technology providers

        Top developments

        • GSK and Genmab (Denmark) reported results of concluded pivotal trial of Arzerra (ofatumumab) for the treatment of CLL patient refractory to fludarabine and alemtuzumab
        • GSK and Genmab (Denmark) obtained European Commission (EC) grant for Arzerra.
        • Roche obtained U.S. FDA approval for Rituxan in combination with fludarabine and cyclophosphamide (FC) for the treatment of CD20-positive chronic lymphocytic leukemia
        • Genzyme declared data from CAM314 randomized phase III clinical trial of Campath (alemtuzumab) along with Fludara (fludarabine phosphate) compared to only Fludara for refractory chronic lymphocytic leukemia.
        • Roche stated pivotal phase III CLL8 three-year follow up results for untreated chronic lymphocytic leukemia.
        • GSK and Genmab (Denmark) obtained accelerated U.S. FDA approval for Arzerra
        • Roche received European Commission approval for rituximab (MabThera) for the treatment of relapsed or refractory chronic lymphocytic leukemia.
        • Genentech and Biogen Idec submitted two Biologics License Applications (sBLAs) to the U.S. FDA for Rituxan plus standard chemotherapy
        • Genzyme acquired marketing rights of Campath from Bayer HealthCare.
        • The European Medicines Agency (EMEA) approved the Marketing Authorization Application (MAA) of GSK and Genmab for Arzerra

1 Introduction
1.1 Analyst Insights
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
2 Executive Summary
3 Market Overview
4 By Geographies
4.1 USA
4.2 Canada
4.3 United Kingdom
4.4 Germany
4.5 France
4.6 Italy
4.7 Spain
4.8 Japan
5 By Companies
5.1 Genzyme Corporation
5.2 Glaxosmithkline Plc
5.3 F. Hoffmann-La Roche Ltd.
5.4 Teva Pharmaceuticals, Inc (cephalon)

Please fill in the form below to receive a free copy of the Summary of this Report

Global Campath/MabCampath Market Research Report

* Enter the text from the image to the text box :

refresh captcha
Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
Connect With Us
US/CAN : +1-888-502-0539